Aortic Valve Replacement for Patients with Heyde Syndrome:A Literature Review

Objective To explore the characteristics and clinical outcomes of patients with Heyde syndrome(HS)who undergo aortic valve replacement(AVR).Methods Electronic databases including Pub Med,Embase,Ovid,WANFANG,VIP and CNKI were searched to identify all case reports of HS patients undergoing AVR surgery,using different combinations of search terms"Heyde syndrome","gastrointestinal bleeding","aortic stenosis",and"surgery".Three authors independently extracted the clinical data including the patients’characteristics,aortic stenosis severity,gastrointestinal bleeding sites,surgical treatments and prognosis.Results Finally,46 case reports with 55 patients aging from 46 to 87 years,were determined eligible and included.Of them,1 patient had mild aortic stenosis,1 had moderate aortic stenosis,42 had severe aortic stenosis,and 11 were not mentioned.Gastrointestinal bleeding was detected in colon(n=8),jejunum(n=6),ileum(n=4),cecum(n=3),duodenal(n=3)and multiple sites(n=8).No specific bleeding site was identified in 23 patients.Preoperative hemoglobin level ranged from 43 to 117 g/L.All but one of 16 patients showed decreased level of high molecule weight von Willebrand factor.Of the 55 patients,43 underwent AVR,and 12 received transcatheter AVR.Aortic valves of 14 cases were replaced by mechanical valves,and 33 cases by biological valves.All patients recovered well during the follow-up,except 5 patients.One patient who had perivalvular leakage and gastrointestinal bleeding after AVR underwent the second AVR.Two patients had recurrent gastrointestinal bleeding.Two patients died of life-threatening acute subdural hematoma and multiple organ failure,respectively.Conclusions HS is a rare syndrome characterized by aortic stenosis and gastrointestinal bleeding.AVR is an effective treatment for HS.

Transcatheter aortic valve implantation in 2015

The last decade has seen transcatheter aortic valve implantation （TAVI） emerge as the standard of care for patients with severe symptomatic aortic stenosis deemed to be either at excessiveor high-risk for surgical aortic valve replacement （SAVR）. This position is supported by three important multicentre randomized trials comparing TAVI to the historical gold standard therapies： （1） The Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve （PARTNER） IB Trial compared TAVI （Edwards SAPIEN, Edwards Lifesciences Inc., Irvine, CA） to optimal medical therapy in patients at excessive surgical risk, and demonstrated an absolute mortality reduction of 〉 20% at 1-year, an effect that was maintained out to 5-year follow-up;Ill （2） The PARTNER 1A Trial compared TAVI （Edwards SAPIEN, Edwards Lifesciences Inc.,

Evaluation of the safety and efficacy of transcatheter aortic valve implantation in patients with a severe stenotic bicuspid aortic valve in a Chinese population

Objective： The purpose of this study is to evaluate the safety and efficacy of transcatheter aortic valve implantation （TAVI） in patients with a severe stenotic bicuspid aortic valve （BAV） in a Chinese population. While several groups have reported the feasibility, efficacy, and safety of TAVI for patients with a BAV, worldwide experience of the technique is still limited, especially in China. Methods： From March 2013 to November 2014, high surgical risk or inoperable patients with symptomatic severe aortic stenosis （AS） who had undergone TAVI at our institution were selected for inclusion in our study. Results were compared between a BAV group and a tricuspid aortic valve （TAV） group. Results： Forty patients were included in this study, 15 （37.5%） of whom were identified as having a BAV. In the BAV group, the aortic valve area was smaller （（0.47±0.13） vs. （0.59±0.14） cm2）, the ascending aortic diameter was larger （（40.4±4.4） vs. （36.4±4.3） mm）, and the concomitant aortic regurgitation was lower. No significant differences were found between the groups in the other baseline characteristics. No differences were observed either in the choice of access or valve size. The procedural success achieved in this study was 100%. There were no differences between groups in device success （86.7% vs. 88.0%）, 30-d mortality （6.7% vs. 8.0%）, or 30-d combined end point （13.3% vs. 12.0%）. The incidences of new pacemaker implantation, paravalvular regurgitation and other complications, recovery of left ventricle ejection fraction and heart function were similar in both groups. Conclusions： Patients with a severely stenotic BAV can be treated with TAVI, and their condition after treatment should be similar to that of people with a TAV.

Mineral metabolism disturbances are associated with the presence and severity of calcific aortic valve disease

Objective：We investigated whether disturbance of calcium and phosphate metabolism is associated with the presence and severity of calcific aortic valve disease （CAVD） in patients with normal or mildly impaired renal function. Methods：We measured serum levels of calcium, phosphate, alkaline phosphatase （AKP）, intact parathyroid hormone （iPTH）, 25-hydroxyvitamin D （25-OHD）, and biomarkers of bone turnover in 260 consecutive patients with normal or mildly impaired renal function and aortic valve sclerosis （AVSc） （n=164） or stenosis （AVS） （n=96） and in 164 age- and gender-matched controls. Logistic regression models were used to determine the association of mineral metabolism parameters with the presence and severity of CAVD. Results：Stepwise increases were observed in serum levels of calcium, phosphate, AKP, and iPTH from the control group to patients with AVS, and with reverse changes for 25-OHD levels （al P〈0.001）. Similarly, osteocalcin, procol agen I N-terminal peptide, andβ-isomerized type I col agen C-telopeptide breakdown products were significantly increased stepwise from the control group to patients with AVS （al P〈0.001）. In patients with AVS, serum levels of iPTH were positively, in contrast 25-OHD levels were negatively, related to trans-aortic peak flow velocity and mean pressure gradient. After adjusting for relevant confounding varia-bles, increased serum levels of calcium, phosphate, AKP, and iPTH and reduced serum levels of 25-OHD were in-dependently associated with the presence and severity of CAVD. Conclusions： This study suggests an association between mineral metabolism disturbance and the presence and severity of CAVD in patients with normal or mildly impaired renal function. Abnormal bone turnover may be a potential mechanism.

Percutaneous balloon aortic valvuloplasty in the treatment of congenital valvular aortic stenosis in children

Objective To assess the effect of the balloon valvuloplasty for congenital valvular aortic stenosis (AS) in children.Methods A total of 27 (mean age 6.09 years) children with AS accepted the treatment of percutaneous balloon aortic valvuloplasty (PBAV). The ratios of balloon/valve were 0.95 ± 0.08 for 19 cases of typical AS and 1.00 ± 0.11 for 8 cases of hypoplastic AS. The patients were evaluated by the gradients across aotic valves in pre- and post-PBAV and by echocardiogram during the follow-up period.Results Fifteen of 19 (78.9％)cases of typical AS had a batter outcome and the gradient of the remaining 4 cases (26.7％) had increased after follow-up (△P ＞ 50 mm Hg) . Four of 8 (50.0％) cases of hypoplastic AS had satisfactory responses and the gradient of the remaining 3 cases (75.0％) rose. There was no moderate to severe aortic insufficiency (Al).Conclusion The balloon aortic valvuloplasty provides safe and significant hemodynamic and clinical improvement in pediatric patients. The outcome of PBAV for typical AS is better than for hypoplastic AS.